NASDAQ:GNPX

Genprex Q1 2025 Earnings Results & Report

Genprex logo
$1.45 -0.22 (-13.17%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.48 +0.03 (+1.72%)
As of 11/20/2026 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genprex beat analyst earnings expectations in its Q1 2025 results, released May 12, 2025. The company reported EPS of -$286.00 versus the -$902.00 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens

Genprex EPS Results

Actual EPS
-$286.00
Consensus EPS
-$902.00
Beat/Miss
Beat by +$616.00
One Year Ago EPS
N/A

Genprex Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Genprex's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

Genprex Q1 2025 Earnings FAQ

Genprex (NASDAQ:GNPX) reported earnings of -$286.00 per share for Q1 2025, beating the consensus estimate of -$902.00. The report was announced on Monday, May 12, 2025.

Genprex's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for Genprex on the company's earnings history page.

Genprex Earnings Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More Genprex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genprex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genprex and other key companies, straight to your email.

About Genprex

Genprex (NASDAQ:GNPX), Inc. is a clinical-stage gene therapy company developing treatments for cancer and diabetes. The company is based in Austin, Texas, and its work focuses on using genetic material to address diseases with significant unmet medical needs.

Its lead cancer candidate, REQORSA (quaratusugene ozeplasmid), is an investigational, non-viral gene therapy designed to deliver the TUSC2 tumor-suppressor gene to cancer cells. Genprex has studied REQORSA in clinical trials for non-small cell lung cancer, including in combination with other cancer therapies.

Genprex is also developing an investigational gene therapy program for diabetes. Its candidates remain in development, and the company’s therapies are not approved for commercial use.

View Genprex Profile